At what enterprise value was MARLE GROUP acquired in 2016?

During the acquisition of MARLE GROUP by IK PARTNERS in 2016, the company was valued at an estimated revenue multiple of below 5x. The transaction's Enterprise Value is estimated to be in the range of 300M - 700M EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of MARLE GROUP when it was acquired by IK PARTNERS?

The estimated EV/EBITDA multiple for MARLE GROUP is in the range of 10x - 18x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was MARLE GROUP acquired by IK PARTNERS?

MARLE GROUP was acquired by IK PARTNERS in 2016.

What was the revenue of MARLE GROUP at the time of the deal?

The revenue of MARLE GROUP at the time of the deal is estimated to be in the range of 50M - 100M EUR. Register for free to access the full transaction report and exact valuation multiples.

What was the EBITDA of MARLE GROUP during the acquisition?

MARLE GROUP's EBITDA is estimated to be in the range of 10M - 30M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the MARLE GROUP acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the MARLE GROUP deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/lbo/ik-investment-partners-valorise-marle-pres-de-350-m-112563

← DATABASE

Home Database Healthcare & PharmaMARLE GROUP

05/2016

MARLE GROUP acquired by IK PARTNERS

FRANCE Life Sciences / Medical Devices / Implants & Prosthetics EV 300M - 700M EUR

Context

IK Investment Partners has agreed to acquire a majority stake in Marle International from Carlyle Europe Technology. The transaction values the company at approximately EUR350 million. This "Limited Auction" process saw IK prevail over competitors Astorg, Permira, and Ergon. As part of the deal, Carlyle reinvests as a minority shareholder, alongside the founding Marle family and the management team. The acquisition aims to support Marle's continued international expansion and external growth strategy.

It is worth noting that the fund The Carlyle Group took control of Marle Group through an LBO in 2009.

MARLE GROUP, which reported an EBITDA margin of LOGIN in 2015, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

Marle Group is a world-leading strategic partner and contract development and manufacturing organization (CDMO) dedicated exclusively to the orthopedic and traumatology industry. Headquartered in France, the company provides a complete, vertically integrated value chain—from initial R&D and design assistance to forging, casting, precision machining, specialized coating, and final sterile packaging. Its business model is built on high-precision industrial expertise, supporting global Original Equipment Manufacturers (OEMs) in the production of hip, knee, shoulder, and spine implants, as well as extremity and trauma devices. The organization operates several state-of-the-art production facilities across Europe and the United States, maintaining the most stringent international regulatory certifications (ISO 13485, FDA). Strategically, the firm acts as a mission-critical consolidator in the MedTech supply chain, benefiting from the structural growth in joint replacement surgeries driven by aging global populations and active lifestyles. Its value proposition is centered on "one-stop-shop" efficiency, technical mastery of biocompatible materials, and a commitment to accelerating the time-to-market for innovative surgical solutions.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2015

2014

Other operations with MARLE GROUP

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
12/2023	MARLE GROUP	NOWAK	FRANCE	Life Sciences	Marle Group has acquired Nowak from a consortium of private equity investors led by Siparex Midcap, alongside Bpifrance, Unexo, and the management team. This acquisition strengthens Marle's vertical integration by adding specialized casting capabilities
10/2019	DENTRESSANGLE	MARLE GROUP	FRANCE	Life Sciences	Dentressangle has entered into exclusive negotiations to acquire a majority stake in Marle Group from IK Investment Partners on a preemptive basis, successfully securing the asset outside of a traditional, highly competitive auction process
09/2009	THE CARLYLE GROUP	MARLE GROUP	FRANCE	Life Sciences	The Carlyle Group has acquired an 80% majority stake in Marle S.A. The company's President, Bernard Marle, along with his family, has reinvested to retain a 20% stake. This Primary LBO is designed to support the company's growth in a market expanding at 8% annually

REFERENCES

Valuation range: EV 300M - 700M EUR

Revenue range: 50M - 100M EUR

EBITDA range: 10M - 30M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of MARLE GROUP by IK PARTNERS are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: marle group

Acquirer: ik partners